Rockefeller Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Rockefeller Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$920K	Buy	3,759 +37	+1%	+$8.02K	﹤0.01%	1756
2026 Q1	$629K	Sell	3,722 -3,731	-50%	-$644K	﹤0.01%	1841
2025 Q4	$1.36M	Buy	7,453 +1,716	+30%	+$240K	﹤0.01%	1414
2025 Q3	$697K	Buy	+5,737	New	+$646K	﹤0.01%	1611
2023 Q1	–	Sell	-350	Closed	-$27K	–	2127
2022 Q4	$27K	Hold	350	–	–	﹤0.01%	2675
2022 Q3	$15K	Hold	350	–	–	﹤0.01%	2890
2022 Q2	$13K	Hold	350	–	–	﹤0.01%	2973
2022 Q1	$14K	Hold	350	–	–	﹤0.01%	2876
2021 Q4	$13K	Hold	350	–	–	﹤0.01%	2831
2021 Q3	$11K	Hold	350	–	–	﹤0.01%	2833
2021 Q2	$23K	Hold	350	–	–	﹤0.01%	2418
2021 Q1	$19K	Hold	350	–	–	﹤0.01%	2295
2020 Q4	$28K	Sell	350 -2,000	-85%	-$150K	﹤0.01%	1872
2020 Q3	$167K	Hold	2,350	–	–	﹤0.01%	1101
2020 Q2	$193K	Hold	2,350	–	–	﹤0.01%	960
2020 Q1	$138K	Buy	+2,350	New	+$191K	﹤0.01%	917

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rockefeller Capital Management's AXSM Position: Q2 2026 in Review

Rockefeller Capital Management increased its Axsome Therapeutics (AXSM) stake by 0.99% in Q2 2026, buying an estimated $8.02K and bringing the position to 3,759 shares worth $920K. The position accounts for ﹤0.01% of the portfolio, ranked #1756.

Rockefeller Capital Management first reported a position in AXSM in Q1 2020 and has held it in 16 quarters since. The position peaked at $1.36M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Rockefeller Capital Management held 3,759 shares of Axsome Therapeutics worth $920K as of Q2 2026.
Rockefeller Capital Management bought 37 Axsome Therapeutics shares in Q2 2026, an estimated $8.02K.
Axsome Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1756 holding.
Rockefeller Capital Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 16 quarters since.
Rockefeller Capital Management's Axsome Therapeutics position peaked at $1.36M in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.